Yahoo Web Search

Search results

1. • Metformin Unveils Its Hidden Talent in Cancer Prevention

     SciTechDaily· 4 days ago

     A study suggests that metformin, typically used for type 2 diabetes, may reduce the risk of myeloproliferative neoplasms (MPN) by leveraging its anti-inflammatory effects to prevent excessive ...

2. • MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com

     ETF DAILY NEWS· 4 days ago

     Equities researchers at StockNews.com began coverage on shares of MEI Pharma (NASDAQ:MEIP – Get Free Report) in a report released on Wednesday. The brokerage set a “buy” rating on the stock.

3. • Aptose Reports Results for the First Quarter 2024

     Digital Journal· 6 days ago

     TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed ...

4. • Syros Pharmaceuticals (NASDAQ:SYRS) Stock Rating Reaffirmed by HC Wainwright

     ETF DAILY NEWS· 2 days ago

     HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price ...

5. • HC Wainwright Cuts Cullinan Oncology (NASDAQ:CGEM) Price Target to $28.00

     ETF DAILY NEWS· 2 days ago

     Cullinan Oncology (NASDAQ:CGEM – Free Report) had its target price decreased by HC Wainwright from $29.00 to $28.00 in a report released on Thursday morning, Benzinga reports. HC Wainwright ...

6. • Small Business - Cordele Dispatch | Cordele Dispatch

     Cordele Dispatch· 4 days ago

     MP0533: Phase 1 trial continues to demonstrate acceptable safety and antitumor activity up to cohort 6, dosing in cohort 7 ongoing, additional dose escalation cohorts being preparedRadio-DARPin Therapy (RDT): Lead DLL3 candidate advancing into

7. • Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to Hold

     ETF DAILY NEWS· 5 days ago

     StockNews.com upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning. Several other ...

8. • Vanguard Personalized Indexing Management LLC Raises Position in Incyte Co. (NASDAQ:INCY)

     ETF DAILY NEWS· 2 days ago

     Vanguard Personalized Indexing Management LLC boosted its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the ...

9. • Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald

     Roanoke-Chowan News-Herald· 6 days ago

     Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug conjugate (SMDC) The National Institutes of Health

10. • Q2 2024 EPS Estimates for Syros Pharmaceuticals, Inc. Increased by HC Wainwright (NASDAQ:SYRS)

      ETF DAILY NEWS· 4 days ago

      Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Free Report) – Research analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Syros Pharmaceuticals in a research report issued to clients ...